Previous Close | 5.65 |
Open | 5.62 |
Bid | 5.56 x 500 |
Ask | 5.60 x 200 |
Day's Range | 5.55 - 5.67 |
52 Week Range | 3.50 - 7.67 |
Volume | |
Avg. Volume | 885,636 |
Market Cap | 697.285M |
Beta (5Y Monthly) | -1.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.57 |
Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.25 |
On August 21, 2024, Paul Bolno, President and Chief Executive Officer of WAVE Life Sciences Ltd (NASDAQ:WVE), executed a sale of 48,366 shares of the company. According to the SEC Filing, the transaction was carried out at an average price of $5.78 per share, totaling approximately $279,575. The insider now owns 359,059 shares of WAVE Life Sciences Ltd.
Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 are on track for 3Q 2024 In previous Part A trial, WVE-N531 achieved industry-leading exon skipping of 53% and muscle tissue concentrations that were approximately 20-30 times higher than those reported by exon skipping technologies leveraging muscle delivery conjugates CAMBRIDGE, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clin
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders are probably feeling a little disappointed, since its shares fell...